Sustained cognitive and functional effects of pro-cognitive interventions for bipolar disorder: A systematic review of randomised controlled trials.

J Affect DisordAug 17, 2026 (epub)
Clinical ResearchPsychiatry

Michail Kalfas, Anna Tröger, Elliot Hampsey et al.

✦ AI-curated · Sources linked

In 30 seconds

This systematic review evaluated the effects of pro-cognitive interventions on cognitive and functional outcomes in individuals with bipolar disorder (BD). It included seven randomized controlled trials (RCTs) with a total of 615 participants. The review found that while cognitive remediation (CR) showed cognitive benefits at 3 to 6 months, consistent functional improvements were observed in only one trial.

Key findings

  • Approximately 13% of identified RCTs assessed cognitive or functional outcomes at least 3 months post-treatment.
  • Three of four RCTs on cognitive remediation reported cognitive benefits at 3 to 6 months.
  • Only one RCT found consistent functional effects at 3 months following cognitive remediation.

Why it matters

Understanding the efficacy of pro-cognitive interventions in BD is crucial for improving patient outcomes. Clinicians need to be aware of the limited evidence regarding the translation of cognitive gains into functional improvements, which can impact treatment planning.

Source

PubMed · PMID 42607892

Published in J Affect Disord. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Psychiatry

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.